Participant flow16

How many started, completed or left each group, period by period.

1 to 16 of 16

Period	Milestone	Group	Participants
Overall Study	STARTED	Liraglutide 0.6 mg	351
Overall Study	STARTED	Liraglutide 1.2 mg	350
Overall Study	STARTED	Liraglutide 1.8 mg	349
Overall Study	STARTED	Placebo	348
Overall Study	Exposed	Liraglutide 0.6 mg	350
Overall Study	Exposed	Liraglutide 1.2 mg	348
Overall Study	Exposed	Liraglutide 1.8 mg	347
Overall Study	Exposed	Placebo	348
Overall Study	COMPLETED	Liraglutide 0.6 mg	300
Overall Study	COMPLETED	Liraglutide 1.2 mg	265
Overall Study	COMPLETED	Liraglutide 1.8 mg	258
Overall Study	COMPLETED	Placebo	274
Overall Study	NOT COMPLETED	Liraglutide 0.6 mg	51
Overall Study	NOT COMPLETED	Liraglutide 1.2 mg	85
Overall Study	NOT COMPLETED	Liraglutide 1.8 mg	91
Overall Study	NOT COMPLETED	Placebo	74

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01836523/flow